View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
March 17, 2022updated 11 Jul 2022 1:54pm

American Red Cross declares blood shortage crisis: impact on sickle cell disease

According to the American Red Cross, there is a decrease in blood donations due to Covid-19 and blood drives should be re-established as SCD cases rise.

By GlobalData Healthcare

In January 2022, the American Red Cross (ARC) issued its first blood crisis, citing an extreme scarcity of blood donations due to the Covid-19 pandemic. According to the ARC, donations have declined 10% since March 2020, including a 62% drop in blood drives at high schools and colleges. This is a major detriment to the US blood supply, as the ARC supplies 40% of the blood products needed and has been reduced to supplying only one in four hospital requests. GlobalData epidemiologists expect that the impacts of the blood shortage will likely result in poorer patient outcomes, especially in those affected by blood disorders like sickle cell disease (SCD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

SCD is an inherited blood disorder, in which sickle-cell traits come from each parent to the child.SCD is so named for the effect the disease has on red blood cells. The hallmark trait of sickle-cell disease is that, instead of the round shape of healthy cells, some red blood cells form into crescent or sickle shapes. These sickle cells can form blood clots and block blood vessels, increasing the risk for deep-vein thrombosis, chronic pain, and stroke.

A fundamental treatment of sickle-cell anaemia is through red blood cell transfusions. The need for transfusions can vary between patients but they can be a lifelong treatment option. These patients are heavily impacted by the ARC blood shortage, as they can be left waiting for available blood as they accumulate the damage of oxygen deprivation. This is further complicated by the limiting factor of blood type: transfusion recipients can only accept the blood of their own type or one with fewer antigens.

In the US, GlobalData epidemiologists forecast that diagnosed prevalent cases of SCD will increase from 109,509 in 2022 to 114,800 in 2030, primarily driven by changes in the underlying population (as shown in Figure 1). However, should the blood crisis continue, an increase in severe patient outcomes and mortality will likely be observed and could lead to diagnosed prevalent cases falling below current forecast estimates. These changes, however, may be temporary as the impacts of the Covid-19 pandemic lessen over time and blood donation levels return to pre-pandemic levels.

There is an urgent need for blood donations in the wake of the Covid-19 pandemic. Because blood cannot be artificially produced or stored long-term, there is a constant requirement for donations. Each red blood cell transfusion requires three units of blood and a car accident victim can require up to 100 units. The ARC specifically requests type O-negative donors, which is the most widely acceptable blood type. It is essential that blood drives and public cooperation are re-established as Covid-19 cases decrease and SCD cases steadily increase.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Related Report
img
Healthcare
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena